Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR

Allergic Rhinitis Clinical Trial

Official title:

Randomized Trial of the Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With Allergic Rhinitis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01880840
• Other study ID #: MP 442
• Status: Completed
• Phase: Phase 4
• First received: June 17, 2013
• Last updated: June 9, 2015
• Start date: June 2013
• Est. completion date: August 2014

Study information

• Verified date: April 2014
• Source: Meda Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in.

Description:

Approximately 200 subjects, between the ages of ≥ 6 months to < 6 years of age who have a history of AR will participate in this study.

The study will be conducted at about 20 research centers in the United States. Each research center will enroll approximately 2 to 10 subjects.

The study will involve at least 4 office visits over at least a 4-week period. You will need to keep the appointments as scheduled by the study personnel.

Some medications or therapies could interfere with the safety evaluations conducted in this study. If your child is currently taking any of these medications or therapies, they will need to discontinue them in order to be eligible for this study. Your study doctor will discuss this with you along with information on how this could affect your child's health. If you and the study doctor decide this is appropriate, there is a specific time period that these will need to be discontinued before your child can proceed in study evaluation.

If your child is eligible for study participation, he/she will be randomly assigned (by chance, like the flip of a coin) to one of the following two study drug groups:

• Astepro (azelastine hydrochloride) 0.15% Nasal Spray, 822 mcg (total daily dose); OR

• Astepro (azelastine hydrochloride) 0.1% Nasal Spray, 548 mcg (total daily dose)

The following are being performed for the purposes of this study and are not considered standard care:

• Your child will be placed in one of the two study drug groups by chance.

• You will complete questionnaires about your child's allergy symptoms.

• You will complete diary cards each morning recording your child's allergy symptoms over the previous 24 hours.

• Your child will have his/her vital signs measured (blood pressure, pulse, temperature and breathing rate).

• You and your child will be asked questions regarding your child's use of any medication or supplements and how your child has felt since his/her last visit.

• Blood and urine samples will be collected to assess the safety of taking the study drug.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 191
• Est. completion date: August 2014
• Est. primary completion date: April 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 6 Months to 5 Years

Eligibility

Inclusion Criteria:

• Male and female subjects >6 months to <6 years, inclusive at the screening visit

• A history of AR

• The parent must provide written informed consent and the child must provide assent, if possible

• Willing and able to comply with the study requirements

• May benefit from treatment with Astepro Nasal Spray, based on the Investigator's assessment (based on medical history, physical examination, etc.) of the subject's clinical condition, at both the Screening and Randomization Visits

• General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer

• Subjects receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections do not preclude participation)

Exclusion Criteria:

• On nasal examination, subjects with superficial nasal mucosal erosion, moderate nasal mucosal erosion, nasal mucosal ulceration, nasal septum perforation

• Other nasal disease(s) likely to affect deposition of intranasal medication, such as acute sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities

• Nasal surgery or sinus surgery within the previous year

• Chronic sinusitis

• The use of any investigational drug within 30 days prior to Visit 1. No investigational products are permitted for use during the conduct of this study

• Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)

• Respiratory tract infections within two weeks prior to Visit 1.

• Subjects with significant pulmonary disease including asthma. Subjects with intermittent asthma who only require short-acting inhaled bronchodilators are eligible for enrollment. Asthma (with the exception of intermittent asthma). Subjects with intermittent asthma who only require short-acting inhaled bronchodilators (not more often than twice per week) and who do not have nocturnal awakening as a result of asthma are eligible for enrollment

• Chronic obstructive sleep apnea syndrome (clinical diagnosis)

• Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug or that might significantly affect the subject's ability to complete this trial

• Clinically relevant abnormal physical findings or laboratory results which, in the opinion of the investigator, would interfere with the objectives -- Family members of research center or private practice personnel who are directly involved in this study are excluded

• Members of the same family cannot enroll in the study at the same time.

• Subjects who have used medications or therapies that could interfere with safety evaluations (see Section 4.0)

• Any behavioral condition which could affect subject's ability to accurately report symptoms to the caregiver such as developmental delay, attention deficit disorder, and autism

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Allergic Rhinitis
• Rhinitis

Intervention

Drug:
• 205.5 mcg of azelastine hydrochloride
nasal spray
• 137 mcg of azelastine hydrochloride
nasal spray

Locations

Country	Name	City	State
United States	Clinical Research Center of Alabama,LLC	Birmingham	Alabama
United States	National Allergy, Asthna & Urticaria Centers of Charleston Pa	Charleston	Pennsylvania
United States	Storms Clinical Research Institute	Colorado Springs	Colorado
United States	West Coast Clinical Trials	Costa Mesa	California
United States	Texas Allergy Research Center	Dallas	Texas
United States	Little Rock Allergy and Asthma Clinical research Center	Little Rock	Alaska
United States	Southern California Research	Mission Viejo	California
United States	Central Texas Health Research	New Braunfels	Texas
United States	Sneeze, Wheeze and Itch Associates	Normal	Illinois
United States	Allergy, Asthma & Clinical Research Center	Oklahoma City	Oklahoma
United States	Live Oak Allergy and Asthma Clinic	San Antonio	Texas
United States	Paul H Ratner,MD	San Antonio	Texas
United States	Allergy and Asthma Center	Waco	Texas
United States	Pediatric Allergy,Asthma and Immunology/Allergy& Asthma care of Waco	Waco	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Meda Pharmaceuticals	Novella Clinical

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety	The objective of this clinical trial is to evaluate the safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray at a dosage of 1 spray per nostril twice daily in subjects =6months to <6 years of age with allergic rhinitis.; Safety will be assessed on the basis of reported adverse experiences, nasal examinations, laboratory evaluations, and vital signs assessments.; Data for each age strata will be summarized separately as well as combined.	one month of treatment	Yes